Kura Oncology, Inc.
KURA
$9.49
-$0.67-6.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 35.73% | 8.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 35.73% | 8.36% | |||
| Cost of Revenue | -94.88% | 12.17% | |||
| Gross Profit | 136.92% | -13.45% | |||
| SG&A Expenses | 30.47% | 10.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.55% | 11.61% | |||
| Operating Income | -10.09% | -12.31% | |||
| Income Before Tax | -12.09% | -15.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.09% | -15.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.09% | -15.14% | |||
| EBIT | -10.09% | -12.31% | |||
| EBITDA | -10.20% | -12.38% | |||
| EPS Basic | -12.01% | -14.90% | |||
| Normalized Basic EPS | -12.02% | -15.35% | |||
| EPS Diluted | -12.01% | -14.90% | |||
| Normalized Diluted EPS | -12.02% | -15.35% | |||
| Average Basic Shares Outstanding | 0.07% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||